Xalkori (crizotinib)

pCPA File Number: 20816
Negotiation Status:
Concluded with an LOI
Indication(s):
Non-Small Cell Lung Cancer (First Line)
Sponsor/Manufacturer:
Pfizer Canada ULC
CDA-AMC Project Number:
PC0054-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: